Photo of Brian R. Overholser
Brian R. Overholser
Professor of Pharmacy Practice
Phone: 317-278-4001
Fax: 317-880-0568
2004 Postdoctoral Fellowship in Pharmacokinetics/Pharmacodynamics, Purdue University 2001 PharmD, Purdue University 1997 Pre-Pharmacy, Purdue University

Dr. Brian R. Overholser, PharmD, FCCP, is a Professor at the Purdue University College of Pharmacy and Adjunct Professor in the Division of Clinical Pharmacology at the Indiana University School of Medicine. He also serves as the director for Graduate Programs in Clinical Pharmaceutical Sciences and Health Services, Outcomes, and Policy in the College of Pharmacy. The goal of his research program is to identify mechanisms toward the pathologic regulation of voltage-gated ion channels using cellular and animal models that are translatable to clinical practice. His multidisciplinary research team has published over 50 original research papers in addition to 14 book chapters. This translational research has received funding from the National Institutes of Health, Showalter Trust, Lilly Endowment, American College of Clinical Pharmacy, and the American Heart Association. Dr. Overholser contributes to the teaching mission by coordinating the core Pharmacogenomics course in the College of Pharmacy and is an instructor in several graduate and professional courses related to Clinical Pharmacology and Pharmacokinetics at both Purdue University and through the T32 Clinical Pharmacology program in the Division of Clinical Pharmacology.

Lab Members
Omar Ali Aboshady (Graduate Student)
Enoch Amarh (Graduate Student)
Michael Majebi Attah (Graduate Student)
Noha F. Keshk (Graduate Student)
Jacob Andrew Lindsey (Graduate Student)
Elissa E. Min (Graduate Student)
Muganyizi Dominic (Ganyi) Mutalemwa (Graduate Student)
Wilberforce Asiedu Osei (Graduate Student)
Jess Zacharia Raffa (PharmD/PhD Student)
Min Yue (Graduate Student)

PHRM 847: Principles of Pharmacogenomics

PHRM 835: Introduction to Pharmacokinetics

CLPH 690: Population Pharmacokinetics

Representative Publications
  1. Assiri A, Mourad N, Shao M, Kiel P, Skaar TC, Overholser BR. microRNA 362-3p Reduces hERG-Related Current and Inhibits Breast Cancer Cells Proliferation. Cancer Genomics and Proteomics. 2019. Nov;16(6):433-442.
  2. Al-Makki A, Frost K, Yun SA, Overholser B, Shepler B. Ergocalciferol Versus Cholecalciferol in Non-Dialysis Dependent Chronic Kidney Disease Patients: A Small Retrospective Cohort Study. J Pharm Pharm Sci. 2019;22(1):593-598.
  3. Shugg T, Egly C, Stamatkin CW, Patil AS, Tisdale JE, Overholser BR. Progesterone Metabolites Inhibit the Human Ether-a-go-go Related Gene and Predict QT Interval Length. J Clin Pharmacol. 2019 Dec 12. doi: 10.1002/jcph.1563. [Epub ahead of print].
  4. Packiasabapathy S, Aruldhas BW, Horn N, Overholser BR, Quinney SK, Renschler JS, Sadhasivam S. Pharmacogenomics of Methadone. 2020; 21(12): 871-887. 
  5. Shugg T, Somberg JC, Molnar J, and Overholser BR. Inhibition of Outward Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestolol. JACC; Clinical Electrophysiology. 2020; 6(7): 756-759.
  6. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Fisch M, Rodgers JE, Aldemerdash A, Hsu CC, Wang N, Muensterman ET, Rao V, Kovacs RJ. Enhanced Response to Drug-Induced QT Interval Lengthening in Patients with Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. 2020; 26(9): 781-785.
  7. Shugg T, Hudmon A, Overholser BR. Neurohormonal Regulation of IKs in Heart Failure: Implications for Ventricular Arrhythmogenesis and Sudden Cardiac Death. J Am Heart Assoc. 2020 Sep 15;9(18):e016900.
  8. Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C, Kovacs RJ, Tisdale JE. Transdermal Testosterone Attenuates Drug-Induced Lengthening of Both Early and Late Ventricular Repolarization in Older Men. Clin Pharmacol Ther. 2021. 109(6): 1499-1504.
  9. Shugg T, Dave N, Amarh E, Assiri AA, Pollock KE, Overholser BR. Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. Basic Clin Pharmacol Toxicol. 128(3): 357-365.
  10. Sadhasivam S, Aruldhas BW, Packiasabapathy S, Overholser BR, Zhang P, Zang Y, Renschler JS, Fitzgerald RE, Quinney SK. A novel perioperative multi-dose methadone-based multi-modal analgesic strategy in children achieved safe and low analgesic blood methadone levels enabling opioid sparing sustained analgesia with minimal adverse effects. Anesthesia and Analgesia. 2021. 1;133(2): 327-337.
  11. Packiasabapathy S, Aruldhas BW, Zhang P, Overholser BR, Quinney SK, Sadhasivam S. Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children. Pharmacogenomics. 2021. 22(10): 591-602.
  12. Huang L, Assiri AA, Wen P, Zhang K, Fan J, Xing T, Liu Y, Zhang J, Wang Z, Su Z, Chen J, Xiao Y, Wang R, Na R, Yuan L, Liu D, Xia J, Zhong L, Liu W, Guo W, Overholser BR, Peng Z. The CYP3A5 genotypes of both liver transplant recipients and donors influence the time-dependent recovery of tacrolimus clearance during the early stage following transplantation. Clinical and Translational Medicine. 2021. 11(10): e542.
  13. Aruldhas BW, Quinney SK, Overholser BR, Heathman M, Masters A, Ly R, Gao H, Packiasabapathy S, Sadhasivam S. Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children. CPT: Pharmacometrics & Systems Pharmacology. 2021. 10(10): 1183-1194.
  14. Rowe EJ, Shugg T, Ly RC, Philips S, Rosenman MB, Callaghan JT, Radovich M,Overholser BR, Schneider BP, Tisdale JE, Skaar TC. Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer. Frontiers in Cardiovascular Medicine. 2022. 5;9: 894623.